[Translation] A randomized, open-label, single-dose, two-sequence, four-period, fully repeated crossover bioequivalence study of levothyroxine sodium tablets (100 μg) in Chinese healthy subjects under fasting conditions
主要研究目的:按有关生物等效性试验的规定,选择Merck Healthcare Germany GmbH为持证商的左甲状腺素钠片(商品名:Euthyrox®,规格:100μg)为参比制剂,对深圳市中联制药有限公司生产并提供的受试制剂左甲状腺素钠片(商品名:加衡®,规格:100μg)进行空腹给药人体生物等效性试验,比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内,评估两种制剂在空腹给药条件下的生物等效性。
次要研究目的:观察健康受试者口服受试制剂左甲状腺素钠片(商品名:加衡®,规格:100μg)和参比制剂左甲状腺素钠片(商品名:Euthyrox®,规格:100μg)的安全性。
[Translation] Main purpose of study: According to the relevant provisions of bioequivalence test, the levothyroxine sodium tablets (trade name: Euthyrox®, specification: 100μg) of Merck Healthcare Germany GmbH as the licensee were selected as the reference preparation, and the test preparation levothyroxine sodium tablets (trade name: Jiaheng®, specification: 100μg) produced and provided by Shenzhen Zhonglian Pharmaceutical Co., Ltd. were subjected to fasting human bioequivalence test to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions.
Secondary purpose of study: To observe the safety of oral administration of the test preparation levothyroxine sodium tablets (trade name: Jiaheng®, specification: 100μg) and the reference preparation levothyroxine sodium tablets (trade name: Euthyrox®, specification: 100μg) in healthy subjects.